News ImmuneRegen NewsImmuneRegen BioSciences Delivers Protocol for Upcoming Study With Roche's Stockpiled Antiviral TamifluMarch 1, 2007 ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBO), announced today that as a result of ImmuneRegen's recent successful study of its immunomodulator Viprovex(TM), which successfully prevented adverse effects from H3N2 avian influenza, that it would study Viprovex in conjunction with Tamiflu, the FDA-approved neuraminidase inhibitor used to treat, and as a pre-exposure prophylactic, to protect against influenza. In a previous experiment performed in cotton rats at Virion Laboratories, Viprovex successfully prevented the decreases in temperature and weight in cotton rats exposed to H3N2 avian influenza. The most recent study confirmed decreases in viral titers in animal nose and lungs correlate with these indications of well-being, which were seen in Viprovex-treated animals despite influenza infection. "In light of the reproducibility of these findings, and the cytokine data acquired previously, we feel it is prudent to commence a study adding Viprovex treatments to animals being treated post-infection or prophylactically with Tamiflu," said Hal Siegel, Ph.D. Senior Director of Product Development and Regulatory Affairs, ImmuneRegen BioSciences, Inc. Tamiflu (oseltamivir, Roche Pharmaceuticals) is an FDA-approved treatment and prophylactic against influenza and is being purchased and stockpiled by people and governments worldwide in anticipation of a feared pandemic influenza outbreak. ImmuneRegen's Viprovex(TM) has shown the ability to lower influenza viral titers in both lungs and nasal passages in a cotton rat model of influenza, as well as diminish the temperature and weight loss indications of infection. If these studies reflect an ability to treat influenza in humans, the administration in conjunction with Tamiflu might reveal additive impact on treating or preventing influenza. About Virion Systems, Inc. About Radilex(TM) and Viprovex(TM) About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|